UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Romero C
(2022)
Exploring the genetic overlap between 12 psychiatric disorders
Romero C
(2022)
Exploring the genetic overlap between twelve psychiatric disorders.
in Nature genetics
Romero-Garcia R
(2023)
Transcriptomic and connectomic correlates of differential spatial patterning among gliomas.
in Brain : a journal of neurology
Ronaldson A
(2021)
Associations between physical multimorbidity patterns and common mental health disorders in middle-aged adults: A prospective analysis using data from the UK Biobank.
in The Lancet regional health. Europe
Ronaldson A
(2022)
Associations between air pollution and multimorbidity in the UK Biobank: A cross-sectional study
in Frontiers in Public Health
Roscoe C
(2022)
Green Walkability and Physical Activity in UK Biobank: A Cross-Sectional Analysis of Adults in Greater London.
in International journal of environmental research and public health
Roscoe C
(2022)
Associations of private residential gardens versus other greenspace types with cardiovascular and respiratory disease mortality: Observational evidence from UK Biobank.
in Environment international
Roscoe C
(2022)
Associations of greenspace, including private residential gardens, with COVID-19 laboratory-confirmed positive test, hospitalisation and mortality in UK Biobank
in ISEE Conference Abstracts
Roselli C
(2018)
Multi-ethnic genome-wide association study for atrial fibrillation.
in Nature genetics
Rothwell JA
(2022)
Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data.
in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Rowlands AV
(2021)
Association of working shifts, inside and outside of healthcare, with severe COVID-19: an observational study.
in BMC public health
Rowlands AV
(2021)
Association Between Accelerometer-Assessed Physical Activity and Severity of COVID-19 in UK Biobank.
in Mayo Clinic proceedings. Innovations, quality & outcomes
Roy AS
(2020)
Response to 'Vitamin D concentrations and COVID-19 infection in UK Biobank'.
in Diabetes & metabolic syndrome
Rubinacci S
(2022)
Imputation of low-coverage sequencing data from 150,119 UK Biobank genomes
Ruderfer DM
(2020)
Significant shared heritability underlies suicide attempt and clinically predicted probability of attempting suicide.
in Molecular psychiatry
Rudnicka AR
(2022)
Artificial intelligence-enabled retinal vasculometry for prediction of circulatory mortality, myocardial infarction and stroke.
in The British journal of ophthalmology
Ruijsink B
(2020)
Fully Automated, Quality-Controlled Cardiac Analysis From CMR: Validation and Large-Scale Application to Characterize Cardiac Function.
in JACC. Cardiovascular imaging
Ruijsink J
(2022)
Left ventricular myocardial tissue characteristics and function among healthy subjects with varying atherosclerotic cardiovascular disease risk
in European Heart Journal
Runolfsdottir HL
(2021)
Allele frequency of variants reported to cause adenine phosphoribosyltransferase deficiency.
in European journal of human genetics : EJHG
Ruth KS
(2020)
Using human genetics to understand the disease impacts of testosterone in men and women.
in Nature medicine
Ruth KS
(2021)
Genetic insights into biological mechanisms governing human ovarian ageing.
in Nature
Rutten JW
(2020)
Broad phenotype of cysteine-altering NOTCH3 variants in UK Biobank: CADASIL to nonpenetrance.
in Neurology
Rutten-Jacobs LC
(2018)
Genetic risk, incident stroke, and the benefits of adhering to a healthy lifestyle: cohort study of 306 473 UK Biobank participants.
in BMJ (Clinical research ed.)
Rutten-Jacobs LCA
(2018)
Genetic Study of White Matter Integrity in UK Biobank (N=8448) and the Overlap With Stroke, Depression, and Dementia.
in Stroke
Rutter CE
(2023)
Exploring regression dilution bias using repeat measurements of 2858 variables in =49 000 UK Biobank participants.
in International journal of epidemiology
Ruzicka F
(2022)
Polygenic signals of sex differences in selection in humans from the UK Biobank.
in PLoS biology
Ruzicka F
(2022)
An unbiased test reveals no enrichment of sexually antagonistic polymorphisms on the human X chromosome.
in Proceedings. Biological sciences
Ryan MC
(2022)
The additive impact of cardio-metabolic disorders and psychiatric illnesses on accelerated brain aging.
in Human brain mapping
Rämö J
(2023)
Genome-wide screen of otosclerosis in population biobanks: 27 loci and shared associations with skeletal structure
in Nature Communications
Rönnegård AS
(2022)
The association between short-term, chronic localized and chronic widespread pain and risk for cardiovascular disease in the UK Biobank.
in European journal of preventive cardiology
Rüeger S
(2018)
Evaluation and application of summary statistic imputation to discover new height-associated loci.
in PLoS genetics
Saarentaus EC
(2023)
Inflammatory and infectious upper respiratory diseases associate with 41 genomic loci and type 2 inflammation.
in Nature communications
Sadler KV
(2023)
Genome-wide association analysis identifies a susceptibility locus for sporadic vestibular schwannoma at 9p21.
in Brain : a journal of neurology
Sae-Jie W
(2022)
Mendelian randomization study of the effect of coronary artery calcification on atherosclerotic cardiovascular diseases.
in Scientific reports
Saevarsdottir S
(2020)
FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease
in Nature
Saevarsdottir S
(2022)
Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset.
in Annals of the rheumatic diseases
Safizadeh F
(2022)
Association of renin-angiotensin-aldosterone system inhibition with Covid-19 hospitalization and all-cause mortality in the UK biobank.
in British journal of clinical pharmacology
Saha P
(2019)
Substantial Cardiovascular Morbidity in Adults With Lower-Complexity Congenital Heart Disease.
in Circulation
Said MA
(2018)
Associations of Combined Genetic and Lifestyle Risks With Incident Cardiovascular Disease and Diabetes in the UK Biobank Study.
in JAMA cardiology
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |